3-Chloro-1H-pyrrolo[2,3-c]pyridine | 1384079-12-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 3-Chloro-1H-pyrrolo[2,3-c]pyridine
• 英文别名: 3-chloro-1H-pyrrolo[2,3-c]pyridine
• CAS: 1384079-12-2
• 化学式: C₇H₅ClN₂
• 分子量: 152.58
• InChiKey: JFVCPZNYTPZOIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS
  申请人：Disarm Therapeutics, Inc.

  公开号：US20220008405A1

  公开（公告）日：2022-01-13

  The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and a neuroprotective agent.
• INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR
  申请人：Disarm Therapeutics, Inc.

  公开号：US20220072019A1

  公开（公告）日：2022-03-10

  The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.
• INHIBITORS OF SARM1
  申请人：Disarm Therapeutics, Inc.

  公开号：US20220194933A1

  公开（公告）日：2022-06-23

  The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
• [EN] INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR<br/>[FR] INHIBITEURS DE SARM1 EN COMBINAISON AVEC NAD+ OU UN PRÉCURSEUR DE NAD+
  申请人：DISARM THERAPEUTICS INC

  公开号：WO2020081923A1

  公开（公告）日：2020-04-23

  The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.
• [EN] INHIBITORS OF SARM1 IN COMBINATION WITH NEUROPROTECTIVE AGENTS<br/>[FR] INHIBITEURS DE SARM1 EN COMBINAISON AVEC DES AGENTS NEUROPROTECTEURS
  申请人：DISARM THERAPEUTICS INC

  公开号：WO2020132045A1

  公开（公告）日：2020-06-25

  The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and a neuroprotective agent.